New Blood Test Distinguishes Broken Heart Syndrome From Heart Attacks

Emergency rooms across the globe may soon have a powerful new tool to differentiate two conditions that look nearly identical but require fundamentally different approaches. Researchers from the University of Zurich and the University of Greifswald have developed and validated a diagnostic scoring system known as the BioTAK score, which can identify Takotsubo syndrome — commonly called “broken heart syndrome” — before invasive cardiac catheterization is performed. The breakthrough, published in the European Heart Journal in 2026, correctly classified nearly 90 percent of patients in an independent validation group of almost 1,800 individuals.

What Is Broken Heart Syndrome?

Takotsubo syndrome is a sudden heart condition that most often affects postmenopausal women and is typically triggered by intense emotional or physical stress. The name derives from the Japanese word for an octopus trap, reflecting the distinctive ballooning shape the left ventricle takes during an episode. Despite its poetic nickname, the condition is medically serious and sometimes life-threatening.

It accounts for approximately 2 percent of patients initially suspected of having a heart attack and up to one in ten women presenting with acute coronary syndrome. Yet distinguishing it from a classic myocardial infarction during those critical first hours of evaluation has long frustrated clinicians. Patients with Takotsubo syndrome can suddenly experience chest pain, abnormal electrocardiogram results, and elevated cardiac enzymes — all hallmark signs that closely mirror a heart attack. The critical difference is that Takotsubo syndrome does not involve blocked coronary arteries, meaning the treatment pathway diverges significantly from that of a typical heart attack.

Why the Distinction Matters

Because the two conditions appear nearly identical at initial presentation, many patients undergo invasive cardiac catheterization before doctors can determine the actual cause of their symptoms. This procedure involves threading a catheter through blood vessels to the heart, injecting contrast dye, and taking X-ray images. While catheterization remains the gold standard for diagnosing blocked arteries, it carries risks — including bleeding, infection, vessel damage, and allergic reactions to contrast agents. For patients whose symptoms stem from Takotsubo syndrome rather than a blocked artery, catheterization may be unnecessary, and the ability to identify these patients earlier could spare them from an invasive procedure during an already frightening medical event.

How the BioTAK Score Works

The BioTAK score combines biological sex with several blood biomarkers linked to different processes in the cardiovascular system. Researchers used artificial intelligence to determine which combination of biomarkers provided the most useful diagnostic information and then incorporated those markers into a clinical decision tool designed for use in emergency settings.

What makes this approach particularly compelling is its foundation in real patient data. The research drew on prospective patient groups from Switzerland, the SPUM-ACS Registry, and the International Takotsubo Registry, known as InterTAK. Established in 2010, InterTAK is one of the world’s largest international research infrastructures focused exclusively on Takotsubo syndrome. The study analyzed data from more than 3,600 patients with either acute coronary syndrome or Takotsubo syndrome, providing a robust evidence base for the scoring system.

In the independent validation group of nearly 1,800 additional patients, the BioTAK score identified Takotsubo syndrome with high accuracy. Using predefined thresholds, the system correctly classified close to 90 percent of participants before they underwent cardiac catheterization, representing a meaningful improvement in early diagnostic capability.

Clues to the Brain-Heart Connection

Beyond its diagnostic utility, the BioTAK score has revealed new information about the biology of Takotsubo syndrome itself. Two newly identified biomarkers included in the score point to an important role for the brain-heart axis, suggesting that the condition develops through mechanisms separate from atherosclerosis — the buildup of plaque in artery walls that drives most heart attacks.

One of the proteins included in the score helps activate a range of neuropeptides involved in stress responses, anxiety, vascular tone, and autonomic nervous system activity. The other protein is associated with the stability of atherosclerotic plaques. Together, these two markers reveal a biological pattern fundamentally different from the one typically seen in a classic heart attack.

• Stress-response neuropeptides: Suggest the nervous system plays a direct role in triggering cardiac dysfunction
• Plaque stability markers: Help distinguish whether symptoms originate from vascular blockage or emotional triggers
• Biological sex: Incorporated because Takotsubo syndrome disproportionately affects postmenopausal women

This biological insight reinforces what clinicians have observed anecdotally for years: broken heart syndrome is not simply a milder version of a heart attack but a distinct condition with its own underlying mechanisms rooted in the interplay between emotional stress, neurological signaling, and cardiovascular function.

Implications for Emergency Care

The researchers are careful to emphasize that the BioTAK score is not a substitute for cardiac catheterization when it is medically necessary. Rather, it could help guide diagnostic procedures more effectively and avoid unnecessary invasive tests in selected patients. In busy emergency departments where rapid triage decisions are critical, having an additional tool to stratify risk could meaningfully change clinical workflows.

Florian A. Wenzl, co-first author of the study at the Center for Molecular Cardiology at the University of Zurich and the Radcliffe Department of Medicine at the University of Oxford, noted that a simple combination of blood biomarkers and biological sex can identify these patients with remarkable accuracy even before cardiac catheterization. The biomarkers simultaneously provide insights into the biological processes that distinguish Takotsubo syndrome from a classic heart attack, offering clinicians both a diagnostic and a mechanistic understanding in a single test.

Christian Templin, director of the Department of Internal Medicine B at the University Medical Center Greifswald and founder of the InterTAK Registry, framed the clinical goal clearly: identifying patients with Takotsubo syndrome earlier and more reliably in the future while also gaining a better understanding of the underlying disease mechanisms. Further research will examine whether adding the BioTAK score to routine clinical care can improve how Takotsubo syndrome is diagnosed and treated across diverse healthcare settings.

The Broader Context of Stress and Heart Health

The BioTAK score arrives at a time when the medical community is increasingly recognizing the profound connection between psychological stress and cardiovascular health. Recent research published in the journal Cardiology Clinics found that mindfulness, gratitude, and optimism training can improve blood pressure and other heart-health markers within just eight to twelve weeks. A 12-week spirituality-based digital intervention achieved one of the largest reductions observed — cutting systolic blood pressure by 7.6 points and central systolic pressure by 4.1 points.

Together, these developments paint a picture of cardiovascular medicine that is expanding beyond cholesterol and blocked arteries to embrace the full complexity of how stress, emotion, and the nervous system shape heart health. The BioTAK score represents a practical clinical application of this evolving understanding, translating the brain-heart connection into an actionable diagnostic tool that could protect patients from unnecessary procedures while ensuring those with true heart attacks receive the urgent intervention they need.

Looking Ahead

As the BioTAK score moves toward potential clinical integration, several questions remain. The study population, while large, was drawn primarily from European registries, and validation in more diverse populations across different healthcare systems will be essential. Additionally, the score’s performance in real-world emergency settings — where time pressures, comorbidities, and atypical presentations are common — may differ from the controlled environment of a research study.

Nevertheless, the development represents a significant step forward in the precision diagnosis of acute cardiac events. For the millions of patients who arrive at emergency departments each year with chest pain and fear, a tool that can quickly and accurately tell doctors whether they are facing a blocked artery or a stress-induced condition could reduce unnecessary procedures, lower healthcare costs, and most importantly, ensure that each patient receives the right treatment at the right time.

---

Edited by Palawan @QUE.COM
Website: https://QUE.COM Intelligence
Sponsored by: https://MAJ.COM AI Autonomous